Company Overview and News
KUALA LUMPUR, June 14 — Bursa Malaysia opened marginally lower today due to Wall Street's weak overnight performance and ahead of the US Federal Reserve's two-day meeting starting today.
KUALA LUMPUR (May 12): The FBM KLCI notched up marginal gains at the midday break today, reversing its earlier losses, lifted by select blue chips.
KUALA LUMPUR (May 12): DPS Resources Bhd shares surged 15% this morning after it won a legal tussle with Hong Leong MSIG Takaful Bhd.
KUALA LUMPUR (May 12): The FBM KLCI remained in negative territory at mid-morning today as Petronas-linked stocks retreated.
KUALA LUMPUR (April 29): Stocks on Bursa Malaysia are expected to trade lower today in line with the overnight fall at global markets, with support seen at 1,660 points.
KUALA LUMPUR (April 28): Based on corporate announcements and news flow today, companies that might be in focus tomorrow (Friday, April 29) include: Westports Holdings Bhd, Eco World Development Group Bhd (EcoWorld), Tasek Corp Bhd, Spritzer Bhd, Pavilion REIT, Petaling Tin Bhd, Karambunai Corp Bhd, GHL Systems Bhd, AirAsia Bhd, Negri Sembilan Oil Palms Bhd (NSOP), Nakamichi Corp Bhd, Sasbadi Holdings Bhd, Pasdec Holdings Bhd, Tiong Nam Logistics Holdings Bhd, Lay Hong Bhd, DPS Resources Bhd, Homeritz Corporation Bhd, Muhibbah Engineering (M) Bhd, Atlan Holdings Bhd and Gadang Holdings Bhd.
KUALA LUMPUR, Jan 11 — Bursa Malaysia remained in the red at mid-morning today, weighed on by losses in heavyweights. At 11.08am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) was quoted at 1,647.28, down 10.33 points. Market breadth was
KUALA LUMPUR, Jan 11 — Shares on Bursa Malaysia remained under pressure at mid-day today, with Petronas-linked stocks leading the top losers counter. At 12.30pm, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) stood at 1,645.13, down 12.48
KUALA LUMPUR, Jan 11 — Bursa Malaysia ended the day lower across-the-board on weak buying support in view of sluggish regional markets and bearish oil prices. At 5pm, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) settled at 1,637.59, down
The FBM KLCI fell 0.75% at the midday break in line with the slump at regional markets. At 12.30pm, the FBM KLCI lost 12.48 points to 1,645.13. Losers…
The FBM KLCI rose 2.48 points or 0.1% after China regulators scrapped its stock market circuit breaker and fixed a stronger midpoint level for yuan transactions.…
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...